Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial.
Freeman SD, Thomas A, Thomas I, Hills RK, Vyas P, Gilkes A, Metzner M, Jakobsen NA, Kennedy A, Moore R, Almuina NM, Burns S, King S, Andrew G, Gallagher KME, Sellar RS, Cahalin P, Weber D, Dennis M, Mehta P, Knapper S, Russell NH.
Freeman SD, et al. Among authors: russell nh.
Blood. 2023 Nov 16;142(20):1697-1707. doi: 10.1182/blood.2023020630.
Blood. 2023.
PMID: 37595359
Free PMC article.